Clinical Focus Target opportunities in oncology and immunology where milciclib and foralumab patients may benefit, with emphasis on CDK and anti-CD3 mediated pathways, leveraging ongoing Phase II trials in thymic carcinoma and autoimmune conditions.

Intranasal Route Prioritize partnerships and outreach around intranasal foralumab formulations for broader autoimmune and neuroinflammatory indications, highlighting recent Phase 2a MS na-SPMS dosing and upcoming conference presentations.

Clinical Momentum Capitalize on active trial programs and upcoming disclosures at scientific conferences to create opportunities for investigator-initiated studies, co-development discussions, and strategic licensing around IL-6R and CD3 assets.

Financial Opportunity Position for fast-follow or partnering deals given the small company size with substantial clinical development ahead; target CRO/partners for clinical and manufacturing collaboration to manage burn rate and de-risk milestones.

Global Outreach Engage regional biotech hubs and biopharma companies active in neurology, MS, IBD, and autoimmune diseases; align messaging around milestone-driven collaborations leveraging the company’s phase II assets and regulatory pathways.